Viridian Therapeutics, Inc. Common Stock
$21.93
-$0.51 (-2.27%)
$21.72Day Range$22.97
Key Statistics
Market Cap
$2.54B
Shares Outstanding
113.3M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jun 18, 2014
Round Lot
100
Locale
US
Trading Data
Day Open
$22.88
Day High
$22.97
Day Low
$21.72
Volume
1.27M
VWAP
$21.97
Prev Close
$22.44
Transactions
--
Acc. Volume
--
About Viridian Therapeutics, Inc. Common Stock
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
PHARMACEUTICAL PREPARATIONSSIC 2834252 employees221 CRESCENT STREET, WALTHAM, MA, 02453617.272.4600IPO Jun 18, 2014US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001590750
- Composite FIGI
- BBG002H242Z5
- Share Class FIGI
- BBG002H24301
- Ticker Root
- VRDN
- SIC Code
- 2834
About Viridian Therapeutics, Inc. Common Stock (VRDN) Stock
Viridian Therapeutics, Inc. Common Stock (VRDN) closed the 2026-09-17 session at $21.93, down 2.27% versus the previous close (-0.51). The stock opened at $22.88 and traded between $21.72 and $22.97 during that session. Session trading volume was 1.3M shares. The volume-weighted average price (VWAP) is $21.97.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Viridian Therapeutics, Inc. Common Stock has a market capitalization of $2.54 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. VRDN is listed on the XNAS exchange. The company employs approximately 252 people. Viridian Therapeutics, Inc. Common Stock is headquartered in WALTHAM, MA. The recorded listing date is 2014-06-18.
On this page you can find market VRDN stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.